Table 1 Demographic and clinical features of the patients at baseline
Gout storytelling N = 152 | Control N = 154 | p value | |
|---|---|---|---|
N (%) or mean (SD) | N (%) or mean (SD) | ||
Age, in years | 64.0 (8.3) | 65.0 (8.0) | 0.29 |
AA race/ethnicity | 152 (100%) | 154 (100%) | 1.0 |
Marital status | |||
Single | 38 (26%) | 37 (25%) | 0.39 |
Married | 59 (40%) | 65 (43%) | |
Divorced | 30 (20%) | 32 (21%) | |
Widowed | 9 (6%) | 10 (7%) | |
Separated | 13 (9%) | 6 (4%) | |
Missing | 3 (2%) | 4 (3%) | |
Annual income, US $ | |||
< $20,000 | 0 (0%) | 0 (0%) | 0.90 |
$20,000–$39,999 | 53 (37%) | 57 (38%) | |
$40,000–$59,999 | 44 (31%) | 45 (30%) | |
$60,000–$99,999 | 28 (20%) | 26 (17%) | |
$100,000–$149,999 | 13 (9%) | 16 (11%) | |
$150,000 and above | 4 (3%) | 5 (3%) | |
Missing | 10 (7%) | 5 (3%) | |
Body mass index (BMI), kg/m2 | 32.9 (5.7) | 32.9 (8.0) | 0.98 |
Gout duration, in years | 3.1 (1.0) | 3.0 (0.9) | 0.43 |
ACR/EULAR 2015 Gout classification criteria scorea | 9.7 (4) | 9.0 (3.4) | 0.07 |
Primary outcome | |||
Mean ULT MPR with MEMSCap™ | 89% (14%) | 87% (16%) | 0.36 |
% With MPR ≥ 80% with MEMSCap™ | 124 (84%) | 119 (78%) | 0.29 |
Secondary outcomes | |||
Voils self-reported non-adherence scaleb | 1.60 (0.8) | 1.40 (0.7) | 0.03 |
Proportion with pt.-reported current gout flare | 27 (18%) | 30 (20%) | 0.79 |
Serum urate, mg/dl | 5.90 (1.8) | 5.70 (1.7) | 0.58 |
SATMED side effects | 14 (9.4%) | 13 (8.8%) | 1.0 |
SATMED subscales | |||
Treatment effectiveness (0–100) | 8.15 (3.2) | 8.12 (3.7) | 0.94 |
Convenience of use (0–100) | 9.37 (3.3) | 9.54 (3.2) | 0.65 |
Impact on daily living/activities (0–100) | 8.85 (2.4) | 8.55 (3.7) | 0.43 |
Medical care (0–100) | 5.97 (2.4) | 5.81 (2.5) | 0.57 |
Undesirable side effects (0–100) | 11.69 (1.1) | 11.53 (1.7) | 0.35 |
Global satisfaction (0–100) | 10.36 (2.1) | 9.69 (2.9) | 0.02 |
Total SATMED composite score (0–100) | 79.98 (14.6) | 78.29 (19.4) | 0.39 |
Gout-specific HRQOL on GAQ-GIS subscales | |||
Gout concern overall | 52.22 (27) | 48.49 (27.2) | 0.23 |
Gout medication side effects | 39.14 (24.3) | 39.38 (24.7) | 0.94 |
Unmet gout treatment need | 36.32 (18.8) | 34.97 (20.3) | 0.55 |
Well-being during attack | 47.25 (25.5) | 45.81 (25.3) | 0.62 |
Gout concern during attack | 55.58 (23.8) | 49.58 (25.7) | 0.03 |
PEMAT-A/V | |||
Understandability (items 1–13) | 92.16 (12.5) | 91.26 (15.7) | 0.58 |
Accountability (items 14–17) | 91.12 (16.6) | 88.64 (21.0) | 0.25 |
BRFSS alcohol use in last 30 days | |||
Days per week with ≥ 1 alcohol drinks | 1.61 (3.5) | 1.95 (4.2) | 0.43 |
Days per month with ≥ 1 alcohol drinks | 3.68 (9.9) | 3.66 (6.4) | 0.98 |
Alcohol drinks per day, median (interquartile range)c | 0 (0, 2) | 0 (0, 2) | 0.56 |
Alcohol drinks ≥ 5 alcohol drinks | 0.81 (2.8) | 0.91 (3.2) | 0.78 |
Largest number of alcohol drinks on any occasion | 1.72 (3.7) | 1.4 (2.1) | 0.36 |
Baseline gout flares | |||
Last/previous 1 month | 1.40 (1.9) | 1.40 (2.8) | 0.88 |
Last/previous 2 month | 2.30 (3.7) | 2.50 (5.5) | 0.79 |
Pill count | 28.0 (44.5) | 30.7 (49.7) | 0.79 |